FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244171106> ?p ?o ?g. }

• W4244171106 abstract "Abstract Purpose To analyze 68Ga-PSMA-617 PET/CT or PET/MR and delayed PET/MR images in patients diagnosed with or suspected of prostate cancer, and to explore the optimal use of PET/CT and PET/MR for initial diagnosis and staging in prostate diseases. Methods Images from conventional scan by 68Ga-PSMA whole-body PET/CT or PET/MR followed by delayed pelvic PET/MR were retrospectively analyzed. Prostatic 68Ga-PSMA uptake was measured as SUVmax1 (conventional scan 1 h post injection) and SUVmax2 (delayed scan 3 h post injection). Age, PSA levels, and SUVmax were compared between benign and malignant cases. The correlation of SUVmax1 and SUVmax 2 was analyzed. Diagnostic performance was evaluated by ROC analysis. Results We enrolled 56 patients with 41 malignant and 15 benign prostate lesions. Fifty-three patients had paired conventional and delayed scans. Age, PSA levels, and SUVmax were significantly different between benign and malignant cases. A good correlation was found between SUVmax1 and SUVmax2. There was significant difference between SUVmax1 and SUVmax2 in the malignant group (p = 0.001). SUVmax1 had superior diagnostic performance than SUVmax2, SUVmax difference and PSA levels, with a sensitivity of 85.4%, a specificity of 100% and an AUC of 0.956. A combination of SUVmax1 with nodal and/or distant metastases and MR PIRADS V2 score had a sensitivity and specificity of 100%. Delayed pelvic PET/MR imaging in 33 patients were found to be redundant because these patients had nodal and/or distant metastases which can be easily detected by PET/CT. Conclusion Combined 68Ga-PSMA whole-body PET/CT and pelvic PET/MR can accurately differentiate benign prostate diseases from prostate cancer and accurately stage prostate cancer. Whole-body PET/CT is sufficient for advanced prostate cancer, and more economic and time-saving than PET/MR. Pelvic PET/MR contributes to diagnosis and accurate staging in early prostate cancer. Imaging at about 1 hour after injection is sufficient in most patients. Trial registration: NCT03756077. Registered 27 November 2018 - Retrospectively registered, https://clinicaltrials.gov/show/NCT03756077" @default.
• W4244171106 created "2022-05-12" @default.
• W4244171106 creator A5005774629 @default.
• W4244171106 creator A5014542823 @default.
• W4244171106 creator A5019206637 @default.
• W4244171106 creator A5028467654 @default.
• W4244171106 creator A5044912511 @default.
• W4244171106 creator A5067881552 @default.
• W4244171106 creator A5080642996 @default.
• W4244171106 creator A5085025467 @default.
• W4244171106 date "2020-11-20" @default.
• W4244171106 modified "2023-09-24" @default.
• W4244171106 title "Optimized application of 68Ga-prostate-specific membrane antigen-617 whole-body PET/CT and pelvic PET/MR in prostate cancer initial diagnosis and staging" @default.
• W4244171106 doi "https://doi.org/10.21203/rs.3.rs-110222/v1" @default.
• W4244171106 hasPublicationYear "2020" @default.
• W4244171106 type Work @default.
• W4244171106 citedByCount "0" @default.
• W4244171106 crossrefType "posted-content" @default.
• W4244171106 hasAuthorship W4244171106A5005774629 @default.
• W4244171106 hasAuthorship W4244171106A5014542823 @default.
• W4244171106 hasAuthorship W4244171106A5019206637 @default.
• W4244171106 hasAuthorship W4244171106A5028467654 @default.
• W4244171106 hasAuthorship W4244171106A5044912511 @default.
• W4244171106 hasAuthorship W4244171106A5067881552 @default.
• W4244171106 hasAuthorship W4244171106A5080642996 @default.
• W4244171106 hasAuthorship W4244171106A5085025467 @default.
• W4244171106 hasBestOaLocation W42441711061 @default.
• W4244171106 hasConcept C121608353 @default.
• W4244171106 hasConcept C126322002 @default.
• W4244171106 hasConcept C126838900 @default.
• W4244171106 hasConcept C127077266 @default.
• W4244171106 hasConcept C2775842073 @default.
• W4244171106 hasConcept C2776235491 @default.
• W4244171106 hasConcept C2780192828 @default.
• W4244171106 hasConcept C2989005 @default.
• W4244171106 hasConcept C71924100 @default.
• W4244171106 hasConceptScore W4244171106C121608353 @default.
• W4244171106 hasConceptScore W4244171106C126322002 @default.
• W4244171106 hasConceptScore W4244171106C126838900 @default.
• W4244171106 hasConceptScore W4244171106C127077266 @default.
• W4244171106 hasConceptScore W4244171106C2775842073 @default.
• W4244171106 hasConceptScore W4244171106C2776235491 @default.
• W4244171106 hasConceptScore W4244171106C2780192828 @default.
• W4244171106 hasConceptScore W4244171106C2989005 @default.
• W4244171106 hasConceptScore W4244171106C71924100 @default.
• W4244171106 hasLocation W42441711061 @default.
• W4244171106 hasOpenAccess W4244171106 @default.
• W4244171106 hasPrimaryLocation W42441711061 @default.
• W4244171106 hasRelatedWork W10158840 @default.
• W4244171106 hasRelatedWork W11963163 @default.
• W4244171106 hasRelatedWork W13258135 @default.
• W4244171106 hasRelatedWork W15900271 @default.
• W4244171106 hasRelatedWork W16320310 @default.
• W4244171106 hasRelatedWork W1965683 @default.
• W4244171106 hasRelatedWork W3088933 @default.
• W4244171106 hasRelatedWork W583589 @default.
• W4244171106 hasRelatedWork W7721817 @default.
• W4244171106 hasRelatedWork W2155798 @default.
• W4244171106 isParatext "false" @default.
• W4244171106 isRetracted "false" @default.
• W4244171106 workType "article" @default.